CBT-I Augmentation of Medication for Drinking in AUD
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Coatesville and Philadelphia, United StatesSee the 2 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 4
- People taking part
- 82 people enrolled
- Started
- 15 Jun 2022
- Ended
- 20 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Cognitive Behavioral Therapy for Insomnia
- Sleep Hygiene Education
- Record updated
- 28 February 2025
- Why it stopped
- Difficulty recruiting patients
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Male and female Veterans between the ages of 18 and 70 years
- A past-year DSM-5 diagnosis of moderate to severe AUD (i.e., meeting 4 of the 11 DSM-5 criteria for AUD)
- Actively drinking alcohol within the past month ( 2 heavy drinking days, defined as 4 drinks/day for women and 5 drinks/day for men)
- Self-reported insomnia of moderate or severe intensity (i.e., an Insomnia Severity Index total score 15)
- Subject has expressed a desire to stop or reduce drinking
- Capacity to comprehend and give informed consent
- Women of child-bearing potential (i.e., who have not had a hysterectomy, bilateral oophorectomy, tubal ligation or is less than two years postmenopausal), must be non-lactating, practicing a reliable method of birth control, and have a negative urine pregnancy test prior to initiation of treatment
Who cannot take part
- Recent (within the 10 days prior to the baseline visit) exposure to licit or illicit opioids as defined by self-report or a positive urine drug screen. Individuals on a prescription low-dose opioid medication for chronic pain are eligible for treatment with TOP only, and positive urine drug screen(s) will not be exclusionary in this case
- Active treatment with opioid medications; Specific to Topiramate treatment
- Current treatment with medications considered a high risk for adverse reactions for TOP treatment, such as carbonic anhydrase inhibitors
- Current serious psychiatric illness (i.e., schizophrenia, bipolar disorder, severe or psychotic major depression, eating disorder, or imminent suicide or violence risk)
- DSM-5 criteria for any other substance use disorder other than alcohol, nicotine, cannabis use disorder, or mild stimulant (cocaine) use disorder
- Patient also agrees not to initiate CBT for alcohol use disorder during the trial or will be discontinued
- A history of hypersensitivity to naltrexone
- A history of hypersensitivity to TOP
- A history of nephrolithiasis
- A history of narrow angle glaucoma
- A current, clinically significant physical disease or abnormality based on history, physical examination, or routine laboratory evaluation
- A transaminase elevation >300% of normal
- General
- Untreated subjects with a diagnosis of moderate-severe obstructive sleep apnea with a total Apnea Hypopnea Index (AHI-T) of 15 events/hour of sleep
- Completed a full course of CBT-I within the past year; Specific to Naltrexone treatment
Where in United States
- Coatesville VA Medical Center, Coatesville, PACoatesville, United States
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PAPhiladelphia, United States
About the trial
What the trial wants to find out
Alcohol Use Disorder (AUD) and insomnia are more prevalent in Veterans than in the general community. Furthermore, insomnia is comorbid in 36-91% of individuals with AUD and jeopardizes recovery by increasing their risk for relapse and complicating their clinical profile. The VA/DoD guidelines recommend four medications for the treatment of AUD by promoting abstinence and a reduction in drinking. Two of these medications (MED) used commonly are naltrexone and topiramate but they do not improve sleep continuity or insomnia. The recommended treatment for insomnia is Cognitive Behavioral Therapy for Insomnia (CBT-I), and it has shown efficacy in improving insomnia but with minimal benefit in improving abstinence. However, these studies have involved subjects in early or sustained remission. The proposed study will evaluate whether augmenting MED with CBT-I, after reducing drinking or achieving abstinence, bolsters recovery in AUD, by decreasing insomnia and improving abstinence. If this strategy shows good clinical results and the findings are replicated in a multi-center trial then the combination of MED with CBT-I should be considered a standard component of the initial management of AUD with insomnia.
The 2 groups in the trial
- MED + CBT-IExisting treatment, for comparison
This arm will consist of patients treated with topiramate, naltrexone, or topiramate + naltrexone on a clinical basis for 6 weeks and then randomized to Cognitive Behavioral Therapy for Insomnia (CBT-I). They will be continued on MED for the next 8 weeks of CBT-I treatment.
Treatment: Cognitive Behavioral Therapy for Insomnia
- MED + SHEPlacebo, for comparison
This arm will consist of patients treated with topiramate, naltrexone, or topiramate + naltrexone for 6 weeks on a clinical basis for 6 weeks and then randomized to Sleep Hygiene Education (SHE). They will be continued on MED for the next 8 weeks of SHE treatment.
Treatment: Sleep Hygiene Education
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Cognitive Behavioral Therapy (CBT-I) Augmentation of Topiramate in Promoting Abstinence in Alcohol Use Disorder (AUD)
- Record updated
- 28 February 2025